The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi) on 10 May 2022, resolved - for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive programme resolved by the Annual General Meeting - on a directed share issue of no more than 2,690,287 redeemable and convertible class C shares.
The meeting also resolved to authorise the Board of Directors to resolve on the repurchase of all issued class C shares by an offer directed to all holders of class C shares. Repurchase under this authorisation may be made on one or several occasions until the Annual General Meeting 2023 and at a price of no less than 100 per cent and no more than 105 per cent of the quotient value of the share.
The Board of Directors has resolved to exercise the repurchase authorisation for the said purpose by repurchasing all issued class C shares against payment of 100 per cent of the quotient value of the share, corresponding to approximately SEK 0.55 per share. Repurchase of the class C shares may be effected during the period 19 July - 10 November 2022.
The company currently holds 11,258,569 own common shares and no own class C shares. Subsequently to the effected repurchase of class C shares above, all repurchased class C shares are intended to be converted to common shares, whereafter the number of own common shares will amount to 13,948,856.
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Providing sustainable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,600 employees across Europe, North America, the Middle East and Asia. In 2021, revenue amounted to SEK 15.5 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com, LinkedIn and YouTube.
Swedish Orphan Biovitrum AB
Postal address SE-112 76 Stockholm
Phone: 46 8 697 20 00
(C) 2022 Electronic News Publishing, source ENP Newswire